Foundation Medicine Reports Identified Patients Likely to Respond to Certain MET Inhibitor Target Therapies, Durable Responses Shown in Presentation at ASCO
June 01, 2015 at 16:01 PM EDT
Foundation Medicine, Inc. (NASDAQ: FMI) today announced new data demonstrating the role of MET exon 14 (METex14) alterations as drivers ...